Revolution Medicines shares promising data around KRAS drug combination
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Revolution Medicines shares promising data around KRAS drug combination" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Oncodaily, Medscape, Yahoo Finance and WSAW. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 134d ago.
Quick answers
Why is "Revolution Medicines shares promising data around KRAS drug combination" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Anirban Maitra։ Data on Zoldonrasib Plus Daraxonrasib in 2nd and 3rd Line Metastatic Pancreatic Cancer Oncodaily · 137d ago
- Practice-Changing Data in GI Oncology Medscape · 137d ago
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Yahoo Finance · 137d ago
- Experimental cancer drug brings time and hope for patients WSAW · 137d ago
- Revolution Medicines shares promising data around KRAS drug combination Endpoints News · 137d ago
Topics
Related trends
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.
Newly discovered pathway fuels production of cancer-driving proteins
Stanford researchers have identified a protein translation pathway involving the METTL13 enzyme that drives cancer growth and drug resistance.
Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
Incyte presents new early clinical data at ESMO for its KRAS G12D-targeted pancreatic and colorectal cancer medicine.
Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout
Verastem advances its experimental KRAS inhibitor to Phase III following positive early data and a major funding round.
Another one: Sounders win 4th straight
The Seattle Sounders extend their winning streak and unbeaten run following a match against the Revolution.
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.